from www.cnn.com1 year agoA monoclonal antibody treatment for Alzheimer's disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. Read at www.cnn.com #people #years #independent #uncertainty #association #side-effects #controversially[add][|| ... ]